Community pharmacists’ attitudes and opinions towards supplying clozapine

Gan, Yuh-Lin; O’Reilly, Claire

doi:10.1007/s11096-018-0676-y

Cited by 4 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stage One respondents were community pharmacy owners, managers or lead pharmacists as they were likely to be involved in decision-making about implementing a clozapine supply service. Survey development was informed by the limited literature on clozapine supply within community pharmacies [25], and research exploring the uptake of other professional services in similar contexts [26, 27]. Survey piloting was undertaken by three community pharmacists and two research supervisors (SM and AW).…”

Section: Methodsmentioning

confidence: 99%

“…However, there is limited detail about the factors that influence a community pharmacy’s decision to implement a clozapine supply service. In 2016, Gan and O’Reilly [25] explored the attitudes of Australian community pharmacists who were currently providing a clozapine supply service. The authors identified numerous benefits for consumers and pharmacists alike, such as better rapport and relationships between both parties, the provision of holistic care, and increased consumer access to clozapine [25].…”

Section: Introductionmentioning

confidence: 99%

“…In 2016, Gan and O’Reilly [25] explored the attitudes of Australian community pharmacists who were currently providing a clozapine supply service. The authors identified numerous benefits for consumers and pharmacists alike, such as better rapport and relationships between both parties, the provision of holistic care, and increased consumer access to clozapine [25]. Ultimately, transitioning eligible consumers from hospital settings to less restrictive models of care, such as community-based prescribing and dispensing, is expected to provide normality, flexibility, improved quality of life, greater satisfaction and reduced stigma for clozapine consumers [15].…”

Section: Introductionmentioning

confidence: 99%

“…Gan and O’Reilly noted in their study that there was no information on the number of community pharmacies in Australia which provided clozapine since the regulatory changes were implemented [25]. Furthermore, the perspectives of Australian community pharmacists who do not dispense clozapine have not yet been explored.…”

Section: Introductionmentioning

confidence: 99%

“…Similar to Gan and O’Reilly [25], this mixed-method exploratory study was conducted in two stages. Stage One was an online Australia-wide survey, and in Stage Two semi-structured interviews were conducted with community pharmacists who did not provide a clozapine service.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Implementing a clozapine supply service in Australian community pharmacies: barriers and facilitators

Wilson

McMillan

Wheeler

2019

J of Pharm Policy and Pract

View full text Add to dashboard Cite

Background Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, although serious adverse effects such as agranulocytosis and cardiomyopathy limit its use. In July 2015, Australian regulations changed to allow community-based prescribing and supply of clozapine for maintenance therapy. However, there is currently no information on the rate of clozapine services available in Australian community pharmacies, or the factors that influence a pharmacist’s decision to provide, or not provide, a clozapine service, particularly from the perspective of those pharmacists who do not offer this service. This study investigated Australian community pharmacies providing a clozapine supply service and the barriers to, and facilitators of, implementing this service. Methods This mixed method exploratory study was conducted in two stages: (1) a brief online survey of community pharmacists Australia-wide; and (2) semi-structured telephone interviews. The survey was conducted between November 2017–January 2018; results were analysed via descriptive statistics. Survey respondents who did not provide a clozapine service were eligible to participate in a telephone interview exploring barriers and facilitators. Interviews were undertaken between December 2017–January 2018 and data analysed thematically. Results A total of 265 pharmacists completed the survey; 51.3% ( n = 136) provided a clozapine service. Consumer demand was a key facilitator ( n = 18/247; 66.1%) and the main barrier to implementing a clozapine service was a perceived lack of need ( n = 70/122; 57.4%). Twelve survey respondents were interviewed; while most participants acknowledged that supplying clozapine in community pharmacies would benefit consumers due to convenience, the lack of training and support led to difficulties in service implementation. Conclusions Although regulatory changes aimed to improve access to clozapine, it is unclear if they have been successful, or to what degree. Community pharmacists were positive about supplying clozapine in the community but identified a need for training and support to raise awareness of the service so that eligible clozapine consumers can be transitioned to community-based care. Further research is needed about the perceptions of clozapine consumers to determine whether the regulatory changes have resulted in positive outcomes for their independence and quality of life.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%